ipilimumab

Home » Classic Medicine » Pharmacology » ipilimumab
ipilimumab2016-11-15T10:47:43+00:00

ipilimumab 

ONCOLOGY

A therapeutic monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4, which prolongs overall survival in patients with advanced melanoma. It may also be effective for managing advanced non-small cell carcinoma of lung and metastatic hormone-refractory prostate cancer

Adverse effects Stomach pain, bloating, constipation, diarrhoea, fever, dyspnoea, dysuria; potentially fatal immune reactions due to T cell activation. 

Other names MDX101, MDX110, Yervoy

Reference NEJM 2013; 369:122-133  

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.